| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rebaudioside N (Reb N) primarily targets and activates the human sweet taste receptor, a heterodimeric G protein-coupled receptor composed of T1R2 and T1R3 subunits . Research on steviol rebaudiosides has demonstrated that these compounds can bind to four different sites on the T1R2/T1R3 receptor complex, including the Venus Flytrap Domains (VFD2 and VFD3) and the transmembrane domains (TMD2 and TMD3) . A total of nine different binding pockets have been identified on the human sweet taste receptor, and the binding of steviol rebaudiosides to multiple sites leads to different signal transduction processes .
|
|---|---|
| ln Vitro |
The compound is primarily characterized by its physicochemical properties. It has a predicted solubility of 0.023 g/L in water at 25°C, indicating that it is practically insoluble . Based on its structural similarity to other steviol glycosides, Reb N is expected to be metabolized by gut microflora through deglycosylation to the common aglycone steviol, though specific in vitro metabolic studies for Reb N are not detailed.
|
| ln Vivo |
As a member of the steviol glycoside family, Reb N is expected to share similar biological properties with other rebaudiosides, including non-caloric sweetening and potential prebiotic-like effects, though specific in vivo study details are not provided.
|
| Enzyme Assay |
Research on the broader class of steviol rebaudiosides has employed heterologous cell-based assays with HEK-293 cells overexpressing the T1R2/T1R3 heterodimer to study sweet taste receptor binding . For membrane protein stabilization, tools such as DIBMA (diisobutylene-maleic acid) Glycerol and Rho1D4-MagBeads have been used to preserve the native lipidic environment of the receptors during binding studies . Computational docking studies have revealed that steviol rebaudiosides can bind to nine different binding pockets on the sweet taste receptor .
|
| ADME/Pharmacokinetics |
esearch on the broader class of steviol rebaudiosides has employed heterologous cell-based assays with HEK-293 cells overexpressing the T1R2/T1R3 heterodimer to study sweet taste receptor binding . For membrane protein stabilization, tools such as DIBMA (diisobutylene-maleic acid) Glycerol and Rho1D4-MagBeads have been used to preserve the native lipidic environment of the receptors during binding studies . Computational docking studies have revealed that steviol rebaudiosides can bind to nine different binding pockets on the sweet taste receptor .
|
| Toxicity/Toxicokinetics |
Rebaudioside N (Reb N) is classified as not a hazardous substance or mixture according to safety data sheets, with no GHS hazard labeling elements required . The compound is not listed as a carcinogen by NTP, IARC Monographs, OSHA, or ACGIH . The product is explicitly labeled for research use only and not for human or veterinary use . Rebaudioside N has been recognized as Generally Recognized as Safe (GRAS) by FEMA (GRAS List 31) . However, the toxicological effects of this product have not been thoroughly studied . Storage recommendations: powder at -20°C in dry, dark conditions for up to 1 year; in solvent at -20°C for 1 month .
|
| References | |
| Additional Infomation |
Rebaudioside N (Reb N) is a minor steviol glycoside naturally present in trace amounts in Stevia rebaudiana leaves . It has the CAS number 1220616-46-5, a molecular weight of 1275.3 g/mol, and a purity specification of ≥98% by HPLC . The IUPAC name describes a complex structure with multiple glucose and rhamnose sugar moieties attached to the steviol aglycone . The compound is a white powder with a solubility that is practically insoluble in water (0.023 g/L at 25°C) . The InChI Key is AKEKAGBWNXIWSS-ZFXKUSSPSA-N . The compound is covered in research related to the binding mechanisms of steviol rebaudiosides to the human sweet taste receptor, which has identified nine different binding pockets on the T1R2/T1R3 receptor complex .
|
| Molecular Formula |
C56H90O32
|
|---|---|
| Molecular Weight |
1275.2946
|
| Exact Mass |
1274.54
|
| CAS # |
1220616-46-5
|
| PubChem CID |
92023638
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-5.5
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
88
|
| Complexity |
2380
|
| Defined Atom Stereocenter Count |
36
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])[C@@]12C(=C([H])[H])C([H])([H])[C@]3(C([H])([H])C([H])([H])[C@]4([H])[C@@](C(=O)O[C@@]5([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O5)O[H])O[C@@]5([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O5)O[H])O[H])O[H])O[C@@]5([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O5)O[H])O[H])O[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]4(C([H])([H])[H])[C@]3([H])C([H])([H])C1([H])[H])C2([H])[H]
|
| InChi Key |
AKEKAGBWNXIWSS-ZFXKUSSPSA-N
|
| InChi Code |
InChI=1S/C56H90O32/c1-19-12-55-10-6-26-53(3,8-5-9-54(26,4)52(76)87-50-44(85-46-38(72)34(68)28(62)20(2)77-46)42(32(66)24(16-60)81-50)83-47-39(73)35(69)29(63)21(13-57)78-47)27(55)7-11-56(19,18-55)88-51-45(86-49-41(75)37(71)31(65)23(15-59)80-49)43(33(67)25(17-61)82-51)84-48-40(74)36(70)30(64)22(14-58)79-48/h20-51,57-75H,1,5-18H2,2-4H3/t20-,21+,22+,23+,24+,25+,26-,27-,28-,29+,30+,31+,32+,33+,34+,35-,36-,37-,38+,39+,40+,41+,42-,43-,44+,45+,46-,47-,48-,49-,50-,51-,53+,54+,55+,56-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| Synonyms |
REBAUDIOSIDE N; 1220616-46-5; RefChem:178704; ((2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy-3-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl) (1R,4S,5R,9S,10R,13S)-13-((2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy)oxan-2-yl)oxy-5,9-dimethyl-14-methylidenetetracyclo(11.2.1.01,10.04,9)hexadecane-5-carboxylate; [(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7841 mL | 3.9206 mL | 7.8413 mL | |
| 5 mM | 0.1568 mL | 0.7841 mL | 1.5683 mL | |
| 10 mM | 0.0784 mL | 0.3921 mL | 0.7841 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
